Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio sull'artrite pediatrica di Certolizumab Pegol (PASCAL)

1 settembre 2026 aggiornato da: UCB BIOSCIENCES GmbH

Uno studio multicentrico in aperto per valutare la farmacocinetica, la sicurezza e l'efficacia di Certolizumab Pegol in bambini e adolescenti con artrite idiopatica giovanile (AIG) a decorso poliarticolare da moderatamente a gravemente attivo

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits.

If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

193

Fase

  • Fase 3

Accesso esteso

Non più disponibile al di fuori della sperimentazione clinica. Vedi record di accesso esteso.

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Argentina
      • Buenos Aires, Argentina
        • RA0043 2
  • Brasile
      • Curitiba, Brasile
        • Ra0043 15
      • Porto Alegre, Brasile
        • Ra0043 14
      • São Paulo, Brasile
        • Ra0043 12
  • Canada
      • Calgary, Canada
        • Ra0043 21
      • Montreal, Canada
        • Ra0043 22
      • Toronto, Canada
        • Ra0043 20
  • Chile
      • Santiago, Chile
        • Ra0043 60
  • Messico
      • Mexico City, Messico
        • Ra0043 32
      • Monterrey, Messico
        • Ra0043 30
      • México, Messico
        • Ra0043 31
      • San Luis Potosí City, Messico
        • Ra0043 33
  • Russia
      • Moscow, Russia
        • Ra0043 41
      • Moscow, Russia
        • Ra0043 43
      • Saint Petersburg, Russia
        • Ra0043 40
      • Tolyatti, Russia
        • Ra0043 42
  • Stati Uniti
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72202
        • Ra0043 71
    • California
      • Los Angeles, California, Stati Uniti, 90027-6062
        • Ra0043 79
      • San Francisco, California, Stati Uniti, 94143
        • Ra0043 84
    • Connecticut
      • Hartford, Connecticut, Stati Uniti, 06106
        • Ra0043 83
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Ra0043 81
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Ra0043 82
      • Chicago, Illinois, Stati Uniti, 60637
        • Ra0043 90
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Ra0043 75
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Ra0043 80
      • Livingston, New Jersey, Stati Uniti, 07039
        • Ra0043 77
    • New York
      • New Hyde Park, New York, Stati Uniti, 11042
        • Ra0043 85
      • New York, New York, Stati Uniti, 10032
        • Ra0043 87
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Ra0043 74
      • Durham, North Carolina, Stati Uniti, 27710
        • Ra0043 76
    • Ohio
      • Avon, Ohio, Stati Uniti, 44011
        • Ra0043 70
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Ra0043 73
      • Cleveland, Ohio, Stati Uniti, 44109
        • Ra0043 78
      • Cleveland, Ohio, Stati Uniti, 44195
        • Ra0043 95
      • Columbus, Ohio, Stati Uniti, 43205-2694
        • Ra0043 86
    • Oregon
      • Portland, Oregon, Stati Uniti, 97227
        • Ra0043 89

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2)
  • Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2)
  • Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA)
  • Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline
  • Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment)
  • If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response
  • If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose

Exclusion Criteria:

  • Study participant has previously been exposed to more than 2 biologic agents
  • Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug
  • Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer
  • Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
  • Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not)
  • Study participant has a history of systemic JIA, with or without systemic features
  • Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication
  • Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related)
  • Study participant has active uveitis or a history of active uveitis within the preceding 6 months
  • Study participant has current, chronic or recurrent clinically significant infections
  • Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening [Visit 1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Certolizumab Pegol

Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
Droga: Certolizumab Pegol (CZP)

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Reduced CZP regimen (after implementation of protocol amendments 4 and 5):

  • 10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
Altri nomi:
  • Cimzia
Droga: Certolizumab Pegol (CZP)

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):

  • 10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
  • ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
Altri nomi:
  • Cimzia

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
Lasso di tempo: Week 16

Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).
Week 16
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48
Lasso di tempo: Week 48

Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL.
Week 48
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16
Lasso di tempo: Week 16

Number of participants with anti-CZP antibodies were reported.
Week 16
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48
Lasso di tempo: Week 48

Number of participants with anti-CZP antibodies were reported.
Week 48
Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
Lasso di tempo: From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication.
From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study
Lasso di tempo: From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure.
From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
Lasso di tempo: Week 16

PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using visual analog scale (VAS): 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • C-reactive protein (CRP)
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
Lasso di tempo: Week 16

PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment (PGA) of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • Childhood Health Assessment Questionnaire (CHAQ) (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
Lasso di tempo: Week 16

PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
Lasso di tempo: Week 16

PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

UCB BIOSCIENCES GmbH

Collaboratori

PRA Health Sciences

Investigatori

  • Direttore dello studio: UCB Cares, 001 844 599 2273 (UCB)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 marzo 2012

Completamento primario (Effettivo)

8 aprile 2024

Completamento dello studio (Effettivo)

8 aprile 2024

Date di iscrizione allo studio

Primo inviato

7 marzo 2012

Primo inviato che soddisfa i criteri di controllo qualità

7 marzo 2012

Primo Inserito (Stimato)

9 marzo 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 settembre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • RA0043

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Periodo di condivisione IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi